Zedula Special Drug Use Observational Study "Ovarian Cancer"
Latest Information Update: 13 Oct 2024
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Takeda
- 13 Oct 2024 New source identified and integrated (Japan Registry of Clinical Trials: jRCT2031210289).
- 28 Sep 2021 Status changed from not yet recruiting to recruiting.
- 31 Aug 2021 New trial record